No statistically significant racial differences in diffuse large B-cell lymphoma (DLBCL) outcomes were found for patients treated within the VHA, according to recent research.
Diffuse large B-cell lymphoma (DLBCL) becomes much more difficult to treat in older patients, according to a new study suggesting that more adults of advanced age be included in clinical trials for new agents.
DURHAM, NC—Recent Food and Drug Administration approvals of chimeric antigen receptor (CAR) T cell therapies and novel immunotherapies have helped to significantly improve outcomes for patients with relapsed and refractory diffuse large B cell lymphoma (R/R DLBCL)....
Patients with monoclonal gammopathy of undetermined significance (MGUS) have been thought to have a less than 1% chance of progressing to multiple myeloma as long as their M-protein levels are below 1.5 g/dL.
JACKSONVILLE, FL—As treatment options for chronic lymphocytic leukemia (CLL) multiply, physicians face an increasing array of sequencing options but have little guidance from clinical trials of the most effective order given each patient’s specific disease...
The ability of white blood cells to make energy is significantly reduced in Gulf War Illness (GWI), which affects approximately 250,000 U.S. veterans, according to a new study finding a measurable biochemical difference in veterans who have the disease.
Already the second-leading cause of cancer death in the United States, colorectal cancer (CRC) is increasing in adults younger than 50. Early-age onset CRC (EAOCRC) is often diagnosed at later stages, which require more intense treatment, according to a new study.
Individuals who have served in the U.S. military have about three times the risk of monoclonal gammopathy of undetermined significance (MGUS) as a similarly aged cohort in the Icelandic iStopMM study.
Venetoclax combinations are common treatments for individuals with acute myeloid leukemia (AML) who are unable to withstand the rigors of intensive induction chemotherapy.
BTK inhibitors have proven to be a powerful tool in CLL treatment and have replaced chemoimmunotherapy as the preferred first-line treatment.
Monoclonal gammopathy of undetermined significance (MGUS) is not considered a hematological condition of concern, yet it is associated with lower overall survival. VA researchers led by Lawrence Liu, MD, of the St. Louis VAMC, explored whether the reduced life expectancy arose from an increased risk of cardiovascular events.
While most blood cancers affect people in their later years, B-cell acute lymphoblastic leukemia (B-ALL) strikes at a much earlier age. It is the most common hematologic malignancy in adults under the age of 40, the age range of 80% of U.S. servicemembers.
A study presented at the 2023 ASH Conference, provided additional evidence for the healthy deployer effect, this time in individuals with non-Hodkin lymphoma.
Plasma cell dyscrasia affects up to 5% of adults. While often asymptomatic, its characteristic clonal expansion of bone marrow plasma cells can also indicate the presence of several hematological malignancies including multiple myeloma.
Glucagon-like peptide 1 (GLP-1) receptor agonists have gained huge popularity as they have demonstrated the ability to substantially reduce both blood-glucose levels and weight. In addition, recent research suggests cardiovascular and renal benefits to their use in certain populations.
As Vietnam-era veterans move into the age range in which most myeloproliferative neoplasms (MPNs) develop, the VA has a keen interest in fully understanding the full impact of exposure to Agent Orange in veterans with these malignancies.
Even though the overall uptake of cardioprotective antihyperglycemic drugs has increased as second-line treatments for Type 2 diabetes mellitus, over the last decade, patients who actually have cardiovascular disease were less likely to be prescribed them compared to those without CVD.
While some guidelines recommend statin use to achieve low-density lipoprotein cholesterol (LDL-C) goal under 70 mg/dL for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in patients at higher risk, others recommend against a target LDL-C level.
How do demographic, social and geographic factors affect glycemic control over time in veterans newly diagnosed with diabetes?
What is the role of anemia in risk of dementia in veterans with chronic kidney disease?
New Research Suggested That Veterans Exposed to Agent Orange Have Increased Risk of Developing Progressive Blood Cancers, Such as MPNs
For the first time, new research findings have suggested that veterans exposed to Agent Orange might be at increased risk of developing progressive blood cancers, such as myeloproliferative neoplasms (MPNs).
In planning and preparing for the future possibility of large-scale combat operations, military medicine might have to decide which wounded warriors can have delayed evacuations. One issue is the need for blood products.
Immune abnormalities persist in young adult classical Hodgkin lymphoma (YAcHL) patients long after cure. Yet, new research presented at the most recent Annual ASH Meeting and Exposition in New Orleans pointed out the difficulties in assessing whether those issues existed prior to diagnosis.
An estimated 1 in 10 Americans and 1 in 4 veterans has diabetes, not only putting them at increased risk for problems such as heart and kidney disease, but also making them more prone to complications such as infection and bleeding following surgery.
Most hospitalizations in military servicemembers for exertional rhabdomyolysis, a syndrome of muscle breakdown following exercise, are associated with heat illness and present with lower creatine kinase levels than cases without associated heat illness, according to a recent study.
Sickle cell trait (SCT), a condition in which a person has one abnormal allele of the hemoglobin beta gene, affects an estimated 5.02% of non-Hispanic blacks, 1.08% of Hispanics and 0.1% of whites in the U.S. military.
In less than two decades, the advent of targeted therapies transformed chronic myeloid leukemia (CML) from a death sentence with a five-year survival rate of just 22% to a chronic condition with five-year survival exceeding 90%.
Patients with acute myeloid leukemia (AML) face difficult choices if their cancer recurs. Without treatment, survival is a matter of months.
Even though the rate of complete remission of acute promyelocytic leukemia (APL) is currently more than 90% because of the use of all-trans retinoic acid (ATRA) with arsenic trioxide (ATO), hemorrhagic mortality has emerged as the most significant barrier to APL-induced remission, according to a new study.
COVID-19 cases range dramatically from severity, from asymptomatic to self-limited influenza-like illness to severe respiratory failure or even death.